Monoclonal Antibody Delivery Using 3D Printed Biobased Hollow μNe3dle Arrays for the Treatment of Osteoporosis
Document Type
Article
Publication Date
8-1-2024
Abstract
Transdermal microneedles have demonstrated promising potential as an alternative to typical drug administration routes for the treatment of various diseases. As microneedles offer lower administration burden with enhanced patient adherence and reduced ecological footprint, there is a need for further exploitation of microneedle devices. One of the main objectives of this work was to initially develop an innovative biobased photocurable resin with high biobased carbon content comprising isobornyl acrylate (IBA) and pentaerythritol tetraacrylate blends (50:50 wt/wt). The optimization of the printing and curing process resulted in mu Ne3dle arrays with durable mechanical properties and piercing capacity. Another objective of the work was to employ the 3D printed hollow mu Ne3dles for the treatment of osteoporosis in vivo. The 3D printed mu Ne3dle arrays were used to administer denosumab (Dmab), a monoclonal antibody, to osteoporotic mice, and the serum concentrations of critical bone minerals were monitored for six months to assess recovery. It was found that the Dmab administered by the 3D printed mu Ne3dles showed fast in vitro rates and induced an enhanced therapeutic effect in restoring bone-related minerals compared to subcutaneous injections. The findings of this study introduce a novel green approach with a low ecological footprint for 3D printing of biobased mu Ne3dles, which can be tailored to improve clinical outcomes and patient compliance for chronic diseases.
Keywords
3D printing, digital, light Processing, microneedles, monoclonal Antibody, osteoporosis
Divisions
phartech
Funders
King Saud University
Publication Title
Molecular Pharmaceutics
Volume
21
Issue
9
Publisher
American Chemical Society
Publisher Location
1155 16TH ST, NW, WASHINGTON, DC 20036 USA